Dried Blood Spot Collection Cards Market

By Application Type;

New Born Screening (NBS), Infectious Diseases Testing, Therapeutic Drug Monitoring, Forensics, CRO/Research and Others

By Card Type;

Whatman 903, Ahlstrom 226, FTA and Others

By End Use;

Hospitals & Clinics, Diagnostics Centers and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn543334105 Published Date: September, 2025 Updated Date: October, 2025

Dried Blood Spot Collection Cards Market Overview

Dried Blood Spot Collection Cards Market (USD Million)

Dried Blood Spot Collection Cards Market was valued at USD 310.21 million in the year 2024. The size of this market is expected to increase to USD 413.19 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.2%.


Dried Blood Spot Collection Cards Market

*Market size in USD million

CAGR 4.2 %


Study Period2025 - 2031
Base Year2024
CAGR (%)4.2 %
Market Size (2024)USD 310.21 Million
Market Size (2031)USD 413.19 Million
Market ConcentrationHigh
Report Pages366
310.21
2024
413.19
2031

Major Players

  • F. Hoffmann-La Roche Ltd
  • QIAGEN
  • Shimadzu Scientific Instruments
  • Eastern Business Forms, Inc
  • Ahlstrom-Munksjö
  • PerkinElmer
  • ARCHIMEDlife
  • CENTOGENE N.V
  • Hemaxis
  • Lipomic Healthcare
  • Gentegra LLC
  • Thomas Scientific

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Dried Blood Spot Collection Cards Market

Fragmented - Highly competitive market without dominant players


The Dried Blood Spot Collection Cards Market is expanding rapidly as these cards become essential in diagnostic programs, especially for early disease screening. More than 60% of newborn health screenings now rely on DBS cards, showcasing their critical role in healthcare. Their affordability and ease of use support widespread adoption in routine testing environments.

Advantages Driving Demand
DBS cards offer simple, stable, and low-volume blood collection solutions, making them ideal for various clinical and laboratory uses. Currently, about 45% of labs apply DBS cards in biomarker research and infectious disease analysis. Their ambient storage capability reduces logistical challenges and boosts efficiency in resource-limited settings.

Utility in Drug Trials and Research
DBS cards are increasingly utilized in clinical research and pharmaceutical trials, especially for blood sample collection in early drug development. Nearly 50% of bioanalytical processes use DBS methods to ensure better patient compliance and reduce operational strain. This trend is helping pharmaceutical companies improve trial efficiency.

Technological Advancements Supporting Growth
Innovations in automated processing and integration technologies are enhancing the functionality of DBS cards. Roughly 40% of clinical labs have adopted automation-ready DBS systems to optimize their workflows. These advances are helping expand the market’s reach across diagnostics, research labs, and healthcare settings.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Application Type
    2. Market Snapshot, By Card Type
    3. Market Snapshot, By End Use
    4. Market Snapshot, By Region
  4. Dried Blood Spot Collection Cards Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Convenience in Sample Collection

        2. Logistics and Shipping Efficiency

        3. Minimized Biohazard Risks

        4. Increasing Demand for Point-of-Care Testing

      2. Restraints
        1. Variability in Sample Quality

        2. Limited Volume of Blood Collection

        3. Potential Hematocrit Interference

        4. Challenges in Analytical Sensitivity

      3. Opportunities
        1. Expansion in Newborn Screening Programs

        2. Growing Applications in Therapeutic Drug Monitoring

        3. Increasing Demand in Infectious Disease Screening

        4. Adoption in Biomarker Discovery and Validation

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Dried Blood Spot Collection Cards Market, By Application Type, 2021 - 2031 (USD Million)
      1. New Born Screening (NBS)
      2. Infectious Diseases Testing
      3. Therapeutic Drug Monitoring
      4. Forensics
      5. CRO/Research
      6. Others
    2. Dried Blood Spot Collection Cards Market, By Card Type, 2021 - 2031 (USD Million)
      1. Whatman 903
      2. Ahlstrom 226
      3. FTA
      4. Others
    3. Dried Blood Spot Collection Cards Market, By End Use, 2021 - 2031 (USD Million)
      1. Hospitals & Clinics
      2. Diagnostics Centers
      3. Others
    4. Dried Blood Spot Collection Cards Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Roche
      2. QIAGEN
      3. PerkinElmer
      4. Shimadzu Corporation
      5. Ahlstrom-Munksjö
      6. Pall Corporation / Danaher
      7. Eastern Business Forms, Inc.
      8. Archimed Life Science GmbH
      9. CENTOGENE N.V.
      10. Hemaxis
      11. Whatman plc
      12. GE Healthcare
      13. MilliporeSigma
      14. Lipomic Healthcare
      15. Gentegra LLC
  7. Analyst Views
  8. Future Outlook of the Market